Third degree AV block primary prevention: Difference between revisions

Jump to navigation Jump to search
Line 2: Line 2:
===Overview===
===Overview===
==Primary prevention==
==Primary prevention==
*Effective measurement  for primary prevention of [[atrioventricular block]] due to [[dogoxin toxicity]] in  [[patients]] with [[renal insufficiency]] is avoidance of [[dehydration]], [[electrolytes imbalance]].
*Effective measurement  for primary prevention of [[atrioventricular block]] due to [[dogoxin toxicity]] in  [[patients]] with [[renal insufficiency]] is avoidance of [[dehydration]], and [[electrolytes imbalance]].
* [[Patients]] with renal insufficiency, [[potassium]], [[electrolyte disturbances]], and [[dehydration]] are predisposed to develop [[digoxin toxicity]].
* [[Patients]] with renal insufficiency, [[potassium]], [[electrolyte disturbances]], and [[dehydration]] are predisposed to develop [[digoxin toxicity]].
* Careful monitoring of electrolytes, drug levels, and [[renal function]] is essential in [[patients]] on [[chronic]] [[digoxin ]] therapy.
* Careful monitoring of electrolytes, drug levels, and [[renal function]] is essential in [[patients]] on [[chronic]] [[digoxin ]] therapy.
* [[Patients] on multiple AV nodal blocker agents (e.g., [[beta-blockers]] and [[calcium channel blockers]]) are at an increased risk for the development of [[atrioventricular (AV) block ]].
* [[Patients]] on multiple [[AV nodal blocker]] agents (e.g., [[beta-blockers]] and [[calcium channel blockers]]) are at an increased risk for the development of [[atrioventricular (AV) block ]].
* These [[patients]] should be carefully monitored for [[heart blocks]].
* These [[patients]] should be carefully monitored for [[heart blocks]].



Revision as of 07:22, 1 July 2021

Overview

Primary prevention


References


Template:WikiDoc Sources